Creative Biolabs Advances Antibody-Drug Conjugate Technology with Innovative Engineering Techniques
Creative Biolabs has made significant breakthroughs in antibody-drug conjugate (ADC) development, demonstrating advanced glycosylation engineering and innovative approaches to targeting cancer treatments through bispecific and antibody-oligonucleotide conjugates.
Scientists at Creative Biolabs have developed cutting-edge techniques in antibody-drug conjugate (ADC) technology that could potentially transform cancer treatment strategies. By precisely engineering the Immunoglobulin G Fc (IgG Fc) region, researchers have created more targeted and efficient drug delivery mechanisms that enhance the interaction between antibodies and cellular receptors.
The company's breakthrough involves sophisticated glycosylation modification of the Fc region, which improves ADCs' ability to bind cell receptors and mediate immune responses. This technological advancement enables more precise targeting of cancer cells while maintaining drug stability and effectiveness.
A key innovation is the development of bispecific ADCs, which can simultaneously target two different epitopes on cancer-related receptors. This approach addresses previous limitations in traditional ADC treatments by providing a more nuanced mechanism for attacking tumor cells. Currently, 17 ADCs are approved globally, with over 100 in various research and development stages.
Creative Biolabs has also expanded its research into antibody-oligonucleotide conjugates (AOCs), which combine antibody specificity with oligonucleotide gene-targeting capabilities. Using technologies like DNA-PAINT imaging, these conjugates can label intracellular molecules for advanced scientific research, offering researchers unprecedented insights into disease mechanisms.
The company's comprehensive development services cover the entire ADC process, from initial target screening to final drug conjugation. By designing dual complementary epitope structures targeting key cancer markers such as HER2, EGFR, and c-MET, they are pushing the boundaries of precision medicine and targeted therapeutic approaches.
These advancements represent a significant step forward in developing more effective, targeted therapies that could improve treatment outcomes for patients with complex diseases, particularly in oncology.